AKT1 and gastric cancer: Targeting Rictor/mTORC2 as an anticancer therapy is an attractive prospect, since 68% of GC patients show elevated Akt levels, and mTORC2 is a critical kinase to phosphorylate Ser473 residue for full activation of Akt.